Published: Wed, June 07, 2017
Economy | By Melissa Porter

Opko Health, Inc. (NASDAQ:OPK) Slump -1.64% Pre-Session

Float is the number of shares available for trading of a particular stock. Finally, Guggenheim assumed coverage on Opko Health in a research report on Tuesday, March 14th. The stock was acquired at an average cost of $6.43 per share, with a total value of $771,600.00. (NASDAQ:OPK) traded down 6.26% on Monday, reaching $6.29. $168,908 worth of Opko Health Inc. State Street Corp now owns 10,926,560 shares of the biotechnology company's stock valued at $87,412,000 after buying an additional 3,138,685 shares during the period.

On Tuesday, May 16th, Phillip Md Et Al Frost purchased 27,800 shares of Opko Health stock. While some investors use a particular analyst's stock ratings as guidance, it is important to consider the criteria which they use to determine fair value, since the techniques they use are varied and not all analysts are equally competent.

More recent Opko Health Inc. (NASDAQ:OPK) shares with value of $30,840 were bought by PAGANELLI JOHN A. Logal Adam sold 112,975 shares worth $911,674.

The market capitalization of Opko Health, at $3.37 Billion.

This stock is ahead of its 52-week low with +5.01%. Shares price moved down from its 50 days moving average with -13.97% and remote negatively from 200 days moving average with -30.22%. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. The firm had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The company's quarterly revenue was up 1.8% on a year-over-year basis. Equities research analysts anticipate that Opko Health Inc. will post ($0.20) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of USA and worldwide trademark & copyright law. The original version of this report can be viewed at

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OPK. RK Asset Management LLC raised its stake in shares of Opko Health by 0.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company's stock valued at $210,576,000 after buying an additional 1,112,843 shares during the last quarter. Timber Hill LLC acquired a new position in shares of Opko Health during the first quarter worth about $114,000. Russell Investments Group Ltd. bought a new stake in shares of Opko Health during the fourth quarter worth approximately $648,000. The target implies a 34.02% spike from where the shares are now trading. Following the completion of the transaction, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80.

Several research analysts have issued reports on the company. Analysts set a 12-month price target of $13 a share.

Price targets show what analysts believes a stock will be worth at the end of a certain time period. (NASDAQ:OPK). Css Ltd Limited Liability Company Il reported 0.02% of its portfolio in Opko Health Inc. Finally, Zacks Investment Research raised shares of Opko Health from a "sell" rating to a "hold" rating in a research report on Saturday, February 18th.

Additionally on 12/30/16 Standpoint Research "Reiterates" Opko Health Inc (NASDAQ:OPK) to Buy setting price target at $0 and on 6/16/16 Deutsche Bank "Maintained" the stock to Hold at $10.

Stock is now moving with a negative distance from the 200 day simple moving average of approximately -30.22%, and has a poor year to date (YTD) performance of -32.37% which means the stock is constantly subtracting to its value from the previous fiscal year end price.

Like this: